BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 125 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.63 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $1,000 | -98.0% | 200 | -99.2% | 0.00% | -100.0% |
Q1 2020 | $49,000 | +250.0% | 24,433 | +581.2% | 0.00% | +200.0% |
Q2 2019 | $14,000 | +40.0% | 3,587 | +172.2% | 0.00% | 0.0% |
Q3 2018 | $10,000 | +42.9% | 1,318 | +64.8% | 0.00% | 0.0% |
Q1 2017 | $7,000 | -90.0% | 800 | -96.8% | 0.00% | -90.0% |
Q2 2016 | $70,000 | +311.8% | 24,700 | +311.7% | 0.01% | +400.0% |
Q1 2016 | $17,000 | +142.9% | 6,000 | +650.0% | 0.00% | +100.0% |
Q1 2015 | $7,000 | -87.3% | 800 | -82.2% | 0.00% | -87.5% |
Q4 2014 | $55,000 | +71.9% | 4,500 | +36.4% | 0.01% | +60.0% |
Q3 2014 | $32,000 | -3.0% | 3,300 | +26.9% | 0.01% | +25.0% |
Q2 2014 | $33,000 | – | 2,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |